Unlock instant, AI-driven research and patent intelligence for your innovation.

Modified Phosphatases

a technology of phosphatases and phosphates, applied in the field of phosphatases, can solve problems such as confusion of identity

Inactive Publication Date: 2016-02-18
AM PHARMA
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The modified phosphatases exhibit increased specific activity, stability, and zinc independence, making them suitable for treating inflammatory diseases and conditions with disturbed tissue pH or zinc deficiency, while maintaining activity in broader pH ranges and zinc-deficient conditions.

Problems solved by technology

There is currently some confusion of the identity of these metal ions, as successive attempts to identify them yield different answers.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified Phosphatases
  • Modified Phosphatases
  • Modified Phosphatases

Examples

Experimental program
Comparison scheme
Effect test

example 4

Preparation of Mutants

[0145]The mutants as herein in described and more specific the mutants as described in Tables 4, 5 and 6 are / were prepared by using standard molecular biology techniques.

[0146]The amino acid positions as mentioned in Tables 4 to 6 correspond to the sequences as depicted in FIG. 1. Only the mutated positions are indicated, i.e. only the deviations from the wild type sequences are given. For example mutant 1 of Table 4 is, if compared to the given wild type sequence, unchanged at positions 87, 93 and 429, i.e. position 87 is a K, position 93 is a G and position 429 is an E.

[0147]The mutants will be prepared and checked by standard molecular biology techniques, such as PCR site-directed mutagenesis, restriction enzyme analysis, and sequence analysis.

Example 5

[0148]At t=0 different recombinant alkaline phosphatases containing 450±50 Units were diluted 4000× in diluent buffer (0.025M glycine / NaOH pH 9.6 / 1 mM MgCl2 / 1% mannitol / 0.05% BSA) with different concentrations...

example 1

Dephosphorylation of the Biologically Active Substrate ATP by Different Phosphatases

[0155]ATP at a final concentration of 20 μM was incubated with different concentrations of BIAP, sALPP, sALPI or the chimera catALPI / crownALPP. From Table 9 it is obvious that pNPP chemical activity is not 1:1 related to the activity towards a biological substrate, e.g. ATP. Whereas BIAP and sALPI show more than 50% dephosphorylation of ATP after 90 minutes at 37° C. at concentrations of 0.031 and 0.004 pNPP units, respectively, ALPP and catALPP / crownALPP can only dephosphorylate this amount at concentrations of 0.125 and 0.0625 pNPP units, respectively.

example 2

Liver-Slice Assay Using Different Isoforms of Alkaline Phosophatase

[0156]Upon stimulation with LPS (10 μg / ml), liver slices produce NOx. FIG. 6 shows that in the presence of different recombinant human alkaline phosphatases (sALPI, sALPP, GPI-anchored ALPI, catALPI / crownALPP) at different concentrations, the NOx production was significantly inhibited. In this experiment, bovine derived ALPI was used as a positive control and solvent as a negative control.

[0157]Without the addition of LPS, NOx production by the liver slices was less then 10 μM and was not significantly altered by the presence of the different phosphatases during incubation (data not shown). From this it is concluded that all tested recombinant isoforms of human alkaline phosphatases, regardless of the presence of a GPI anchor have activity towards a biological substrate that is involved in the LPS-induced NOx production.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis, inflammatory bowel disease or other inflammatory diseases, or renal failure. The invention further relates to a method for producing phosphatases.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 14 / 020,269, filed Sep. 6, 2013, which is a continuation of U.S. application Ser. No. 12 / 451,137 (now U.S. Pat. No. 8,557,545), which is a National Stage filing of Int. Appl. No. PCT / NL2008 / 050249, filed Apr. 25, 2008, which claims priority to U.S. Provisional Appl. No. 60 / 926,695, filed Apr. 27, 2007, and European Appl. No. 07107176.5, filed Apr. 27, 2007, each of which is incorporated herein by reference in its entirety.REFERENCE TO A SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB[0002]This application includes a Sequence Listing submitted electronically via EFS-Web (name: “3151—0020003_SequenceListing_ascii”; size: 26,557 bytes; and created on: Mar. 20, 2015), which is hereby incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0003]The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N9/16A61K38/46
CPCC12N9/16C12Y301/03001A61K38/465A61K38/00A61P1/00A61P1/04A61P9/10A61P11/00A61P11/06A61P13/12A61P17/00A61P19/02A61P29/00A61P31/04A61P37/02A61P37/06
Inventor VELDERS, MARKWIN PAULJONK, LUIGI JOHANNES CORNELIUSRAABEN, WILLEMWULFERINK, MARTY BERNARDUS FRANSISCUS
Owner AM PHARMA